Ifosfamide and paclitaxel for recurrent or metastatic uterine carcinosarcoma

Yohei Ohtake; Kazuki Sudo; Yuki Kojima; Takuji Seo; Hitomi Okuma; Tadaaki Nishikawa; Masaya Uno; Takashi Uehara; Mitsuya Ishikawa; Maki Tanioka; Emi Noguchi; Akihiko Shimomura; Kan Yonemori; Tomoyasu Kato; Yasuhiro Fujiwara; Kenji Tamura

Ifosfamide and paclitaxel for recurrent or metastatic uterine carcinosarcoma

Yohei Ohtake, Kazuki Sudo, Yuki Kojima, Takuji Seo, Hitomi Okuma, Tadaaki Nishikawa, Masaya Uno, Takashi Uehara, Mitsuya Ishikawa, Maki Tanioka, Emi Noguchi, Akihiko Shimomura, Kan Yonemori, Tomoyasu Kato, Yasuhiro Fujiwara, Kenji Tamura

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Aim: This study aimed to retrospectively evaluate the efficacy and safety of ifosfamide plus paclitaxel (IT) in Japanese patients with recurrent or metastatic uterine carcinosarcoma. Methods: This study included 15 patients who received IT (ifosfamide [l.6g/m² on days 1-3] and paclitaxel [I35mg/m² on day 1] every 3 weeks) for recurrent or metastatic uterine carcinosarcoma. Results: The overall response rate was 38.4%, and the disease control rate was 92.3%. The median progression-free survival was 7.0 months, and the median overall survival was 9.0 months after initiation of IT therapy. The most common hematological adverse event was Grade 1-2 neutropenia. Peripheral neuropathy of Grade 1 or 2 was observed in 33.3% of cases. There was no treatment-related death. Conclusion: IT therapy showed good efficacy and tolerability in Japanese patients with recurrent or metastatic uterine carcinosarcoma.

Original language	English
Pages (from-to)	1525-1529
Number of pages	5
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	46
Issue number	10
Publication status	Published - Oct 2019
Externally published	Yes

Keywords

Ifosfamide
Paclitaxel
Uterine carcinosarcoma

ASJC Scopus subject areas

Medicine(all)

Cite this

@article{f4a972547c404b59ae493ec93b658015,

title = "Ifosfamide and paclitaxel for recurrent or metastatic uterine carcinosarcoma",

abstract = "Aim: This study aimed to retrospectively evaluate the efficacy and safety of ifosfamide plus paclitaxel (IT) in Japanese patients with recurrent or metastatic uterine carcinosarcoma. Methods: This study included 15 patients who received IT (ifosfamide [l.6g/m2 on days 1-3] and paclitaxel [I35mg/m2 on day 1] every 3 weeks) for recurrent or metastatic uterine carcinosarcoma. Results: The overall response rate was 38.4%, and the disease control rate was 92.3%. The median progression-free survival was 7.0 months, and the median overall survival was 9.0 months after initiation of IT therapy. The most common hematological adverse event was Grade 1-2 neutropenia. Peripheral neuropathy of Grade 1 or 2 was observed in 33.3% of cases. There was no treatment-related death. Conclusion: IT therapy showed good efficacy and tolerability in Japanese patients with recurrent or metastatic uterine carcinosarcoma.",

keywords = "Ifosfamide, Paclitaxel, Uterine carcinosarcoma",

author = "Yohei Ohtake and Kazuki Sudo and Yuki Kojima and Takuji Seo and Hitomi Okuma and Tadaaki Nishikawa and Masaya Uno and Takashi Uehara and Mitsuya Ishikawa and Maki Tanioka and Emi Noguchi and Akihiko Shimomura and Kan Yonemori and Tomoyasu Kato and Yasuhiro Fujiwara and Kenji Tamura",

year = "2019",

month = oct,

language = "English",

volume = "46",

pages = "1525--1529",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "10",

}

TY - JOUR

T1 - Ifosfamide and paclitaxel for recurrent or metastatic uterine carcinosarcoma

AU - Ohtake, Yohei

AU - Sudo, Kazuki

AU - Kojima, Yuki

AU - Seo, Takuji

AU - Okuma, Hitomi

AU - Nishikawa, Tadaaki

AU - Uno, Masaya

AU - Uehara, Takashi

AU - Ishikawa, Mitsuya

AU - Tanioka, Maki

AU - Noguchi, Emi

AU - Shimomura, Akihiko

AU - Yonemori, Kan

AU - Kato, Tomoyasu

AU - Fujiwara, Yasuhiro

AU - Tamura, Kenji

PY - 2019/10

Y1 - 2019/10

N2 - Aim: This study aimed to retrospectively evaluate the efficacy and safety of ifosfamide plus paclitaxel (IT) in Japanese patients with recurrent or metastatic uterine carcinosarcoma. Methods: This study included 15 patients who received IT (ifosfamide [l.6g/m2 on days 1-3] and paclitaxel [I35mg/m2 on day 1] every 3 weeks) for recurrent or metastatic uterine carcinosarcoma. Results: The overall response rate was 38.4%, and the disease control rate was 92.3%. The median progression-free survival was 7.0 months, and the median overall survival was 9.0 months after initiation of IT therapy. The most common hematological adverse event was Grade 1-2 neutropenia. Peripheral neuropathy of Grade 1 or 2 was observed in 33.3% of cases. There was no treatment-related death. Conclusion: IT therapy showed good efficacy and tolerability in Japanese patients with recurrent or metastatic uterine carcinosarcoma.

AB - Aim: This study aimed to retrospectively evaluate the efficacy and safety of ifosfamide plus paclitaxel (IT) in Japanese patients with recurrent or metastatic uterine carcinosarcoma. Methods: This study included 15 patients who received IT (ifosfamide [l.6g/m2 on days 1-3] and paclitaxel [I35mg/m2 on day 1] every 3 weeks) for recurrent or metastatic uterine carcinosarcoma. Results: The overall response rate was 38.4%, and the disease control rate was 92.3%. The median progression-free survival was 7.0 months, and the median overall survival was 9.0 months after initiation of IT therapy. The most common hematological adverse event was Grade 1-2 neutropenia. Peripheral neuropathy of Grade 1 or 2 was observed in 33.3% of cases. There was no treatment-related death. Conclusion: IT therapy showed good efficacy and tolerability in Japanese patients with recurrent or metastatic uterine carcinosarcoma.

KW - Ifosfamide

KW - Paclitaxel

KW - Uterine carcinosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85073600001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073600001&partnerID=8YFLogxK

M3 - Article

C2 - 31631133

AN - SCOPUS:85073600001

SN - 0385-0684

VL - 46

SP - 1525

EP - 1529

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 10

ER -

Ifosfamide and paclitaxel for recurrent or metastatic uterine carcinosarcoma

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this